Methods for treating hematopoietic malignancies

Abstract

The present invention relates to methods for treating neoplasias in a mammalian subject. In particular, the invention provides methods for treating lymphomas, including forms of non-Hodgkin lymphoma. In one embodiment, these methods involve reducing tumor necrosis factor signaling.

1 - 25 . (canceled) 
     
     
         26 . A method for diagnosing a subject as having diffuse large B cell lymphoma (DLBCL), comprising
 a) providing
 i) a test sample from said subject, and 
 ii) a control sample selected from the group consisting of chronic lymphocytic leukemia (CLL) sample and follicular lymphoma (FL) sample, 
   b) measuring the level of at least one marker of DLBCL in said test sample and in said control sample, wherein said marker is selected from the group consisting of inositol polyphosphate-5-phosphatase (SHIP-1) and miR-155, and wherein said measuring comprises contacting said test sample and said control sample with a recombinant polymerase chain reaction (PCR) primer,   c) comparing the level of said at least one marker in said test sample and in said control sample, wherein at least one of reduced expression of said SHIP-1 and increased expression of said miR-155 in said test sample compared to said control sample correlates with DLBCL in said test sample, and   d) diagnosing said subject as having DLBCL.   
     
     
         27 . The method of  claim 26 , further comprising step e) generating a prognosis for the subject that is diagnosed in step d) as having DLBCL. 
     
     
         28 . A method for diagnosing a subject as having diffuse large B cell lymphoma (DLBCL), comprising
 e) providing
 iii) a test sample from said subject, and 
 iv) a control sample selected from the group consisting of chronic lymphocytic leukemia (CLL) sample and follicular lymphoma (FL) sample, 
   f) measuring the level of at least one marker of DLBCL in said test sample and in said control sample, wherein said marker is selected from the group consisting of inositol polyphosphate-5-phosphatase (SHIP-1) and miR-155, and wherein said measuring comprises contacting said test sample and said control sample with an antibody that specifically binds to at least one of SHIP-1 and miR-155,   g) comparing the level of said at least one marker in said test sample and in said control sample, wherein at least one of reduced expression of said SHIP-1 and increased expression of said miR-155 in said test sample compared to said control sample correlates with DLBCL in said test sample, and   h) diagnosing said subject as having DLBCL.   
     
     
         29 . The method of  claim 28 , further comprising step e) generating a prognosis for the subject that is diagnosed in step d) as having DLBCL.